FDA approves Sanofi/Regeneron colon cancer drug

(Reuters) - The U.S. Food and Drug Administration said on Friday that it had approved the Sanofi SA and Regeneron Pharmaceuticals Inc drug Zaltrap for patients with metastatic colorectal cancer whose tumors have failed to respond to earlier treatment with chemotherapy.

08/14/2012

The infused medicine, to be taken in combination with standard chemotherapy, will compete with Roche Holding AG's Avastin and Bristol-Myers Squibb Co's Erbitux.

Industry analysts say they expect Zaltrap to win peak annual sales of perhaps $300 million to $400 million, well below the widely used older treatments.

Patients taking Zaltrap in a large clinical trial, in combination with a standard chemotherapy combination regimen called FOLFIRI, lived an average of 13.5 months, compared with 12 months for those receiving only FOLFIRI. Also, patients receiving Zaltrap went an average 6.9 months before their symptoms got worse, compared with 4.7 months for those on chemotherapy alone.

Zaltrap, like Avastin but through a different approach, blocks a protein called VEGF that tumors employ to create blood vessels that provide the nutrients. Erbitux blocks receptors to a different protein, called epidermal growth factor.

"This is a very solid new opportunity" for Regeneron," said RW Baird analyst Christopher Raymond, who predicted the medicine would garner sales of $205 million in 2015. But Raymond said most proceeds in the next few years will likely go to partner Sanofi, which is entitled not only to a half share of profits from Zaltrap but also to reimbursement from Regeneron for half the drug's development costs funded by Sanofi.

Regeneron is far better known for Eylea, a treatment approved late last year for treating macular degeneration, the leading cause of blindness in the elderly. The eye medicine has the same active ingredient as Zaltrap, called aflibercept, and is already achieving blockbuster sales and stealing market share from Roche's Lucentis treatment for the eye condition.

"While near-term we expect (Regeneron's) stock will continue to trade primarily on the Eylea launch which remains impressive, we view Zaltrap's approval as a nice complement to what is rapidly becoming one of biotech's best commercial stories," Raymond said.

The company, based in Tarrytown, New York, has a promising array of other drugs in development with Sanofi to treat cancer, cholesterol and inflammatory diseases.

Adnan Butt, an analyst with RBC Capital Markets, said he has particularly high hopes for REGN727, which slashed levels of "bad" LDL cholesterol by more than 60 percent in a mid-stage study and is now being tested in far larger Phase III studies. It blocks a protein called PCSK9, a new approach.

He also cited REGN88, a treatment being tested against rheumatoid arthritis that works by blocking a protein called IL-6.

"They are both potential blockbuster medicines," Butt said.

Regeneron shares, which rose 0.4 percent to $136.96 on Friday, have soared 250 percent since the FDA approved Eylea on November 18.

Regeneron research chief George Yancopoulos said anti-angiogenesis drugs, like Zaltrap and Avastin, have not been able to slow down tumor growth nearly as well as researchers had originally hoped.

"We thought if you could choke off the blood supply you could, if not kill the tumor, keep it from growing. But (targeting) VEGF may not be enough, we may have to combine different types of anti-angiogenesis drugs."

Toward that end, Yancopoulos said Regeneron and Sanofi are testing two such medicines, which instead block proteins DLL4 and angiopoietin 2, that could someday be used in combination with anti-VEGF therapies to more fully cut off blood supply to tumors.

Zaltrap, like Avastin, was shown to be ineffective in treating prostate cancer. It also failed in other studies to improve outcomes in patients with lung and pancreatic cancers.

Colorectal cancer is the fourth most commonly diagnosed cancer in the United States, and the fourth leading cause of cancer death, the FDA said. Almost 145,000 Americans are expected to be diagnosed with the disease this year, and almost 52,000 will die from the cancer, according to the National Institutes of Health.

(This story is corrected in paragraph 7 to remove erroneous statement that Lucentis is derived from Avastin)

(Reporting by Ransdell Pierson in New York and David Morgan in Washington; Editing by Lisa Von Ahn, Marguerita Choy and Bernard Orr)

Are you at Risk For Colorectal Cancer?

2nd leading cause of cancer deaths for men and women combined

Colonoscopies not only discover cancer, but can also stop cancer

50% of Americans still do not get colonoscopy reimbursement

Colon cancer research is still vastly under-funded

Events in Your Neighborhood

About

The Chris4Life Colon Cancer Foundation is a national Colon Cancer non profit dedicated to permanently eliminating the threat of the disease through the discovery of a cure. As long as people are dying from this disease, we will be at the front lines of the fight. To this end, we will fund cutting edge research so that the brightest minds and best institutions are empowered to cure colon cancer for good. Until then, Chris4Life Colon Cancer Foundation is committed to significantly improving the treatment experience for patients and caregivers, and to dramatically raise awareness about colon cancer in general. Chris4Life will utilize health and wellness as a means of integrating the mind, body and spirit in our approach. Working together we will build a culture of care and foster relationships with national colon cancer research institutions, non profit advocacy groups, the health care community, and the general public. Chris4Life four core values are Compassion, Empowerment, Perseverance, and Life.